Research Article

Differential Effect of Antioxidants Glutathione and Vitamin C on the Hepatic Injuries Induced by Plasmodium berghei ANKA Infection

Nayara Kauffmann1, Luana K. R. L. da Penha1, Danielle V. Braga1, Brenda J. A. Ataíde1, Nivia S. F. Mendes1,1, Laiane P. de Sousa1,1, Givago S. da Souza2,1, Adelaide C. F. Passos1,1, Evander J. O. Batista3,1, Anderson M. Herculano1,1, and Karen R. H. M. Oliveira1,1,3

1Instituto de Ciências Biológicas, Laboratório de Neurofarmacologia Experimental, Universidade Federal do Pará, Belém, Pará, Brazil
2Núcleo de Medicina Tropical, Laboratório de Neurologia Tropical, Universidade Federal do Pará, Belém, Pará, Brazil
3Núcleo de Medicina Tropical, Laboratório de Protozoologia, Universidade Federal do Pará, Belém, Pará, Brazil

Correspondence should be addressed to Karen R. H. M. Oliveira; oliveirakrm@gmail.com

Received 4 June 2021; Accepted 14 August 2021; Published 6 September 2021

Academic Editor: Praveen Bharti

Copyright © 2021 Nayara Kauffmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Malaria is a life-threatening disease caused by Plasmodium and represents one of the main public health problems in the world. Among alterations associated with the disease, we highlight the hepatic impairment resulting from the generation of oxidative stress. Studies demonstrate that liver injuries caused by Plasmodium infection are associated with unbalance of the antioxidant system in hepatocytes, although little is known about the role of antioxidant molecules such as glutathione and vitamin C in the evolution of the disease and in the liver injury. To evaluate disease complications, murine models emerge as a valuable tool due to their similarities between the infectious species for human and mice. Herein, the aim of this study is to evaluate the effect of antioxidants glutathione and vitamin C on the evolution of murine malaria and in the liver damage caused by Plasmodium berghei ANKA infection. Mice were inoculated with parasitized erythrocytes and treated with glutathione and vitamin C, separately, both at 8 mg/kg during 7 consecutive days. Our data showed that during Plasmodium infection, treatment with glutathione promoted significant decrease in the survival of infected mice, accelerating the disease severity. However, treatment with vitamin C promoted an improvement in the clinical outcomes and prolonged the survival curve of infected animals. We also showed that glutathione promoted significant decrease in the parasitemia rate of Plasmodium-infected animals, although treatment with vitamin C has induced significant decrease in parasitemia rates. Furthermore, histological analysis and enzyme biochemical measurement showed that treatment with glutathione exacerbates liver damage while treatment with vitamin C mitigates the hepatic injury induced by the infection. In summary, the current study provided evidences that antioxidant molecules could differently modulate the outcome of malaria disease; while glutathione aggravated the disease outcome and liver injury, the treatment with vitamin C protects the liver from damage and the evolution of the condition.

1. Introduction

Malaria represents one of the major and oldest public health problems in developing countries [1, 2]. Despite a global fall in mortality rates since 2000, malaria remains a worldwide problem with 228 million cases and 405,000 deaths only in 2018 [3, 4]. In endemic areas, deaths by Plasmodium infection occur as a result of severe complications which include renal failure, acidosis, cerebral malaria, respiratory distress, and severe anaemia followed by liver impairment [5–7].
As widely described in literature, malaria disease is caused by infection with species of *Plasmodium* spp. This parasite presents a complex life cycle involving different stages of development in both mosquito and human hosts [8, 9]. Ookinetes and sporozoites are the life forms of *Plasmodium* found in a definitive mosquito host, and the sporozoites are responsible for infecting hepatocytes in the liver of a vertebrate host. Sporozoites reproduce asexually inside hepatocytes generating exoerythrocytic merozoites which migrate to bloodstream and infect blood erythrocytes [10, 11]. In the vertebrate host, the liver is considered a *Plasmodium* “depository” being an essential organ to the development of malaria disease. Malaria-associated liver injury is common in both adults and pediatric patients and is characterized by an increase in the serum levels of biochemical markers such as bilirubin and aminotransferases [12–14]. Furthermore, Kupffer cell hyperplasia, hemozoin deposition, and monocyte infiltration are also frequent histological alterations described in the malaria hepatopathy [15, 16].

Previous studies demonstrate that liver injuries caused by *Plasmodium* infection are associated with unbalance of the antioxidant system in hepatocytes [17]. However, it remains unclear if treatment with antioxidants is able to protect the liver of infected subjects. Glutathione (GSH) is the main antioxidant in intracellular environment, and the liver represents the most important provider of GSH to organs and tissues [18, 19]. It is also widely documented that vitamin C acts as an essential component for liver homeostasis [20]. Although few studies have demonstrated the beneficial effect of vitamin C on the malaria disease, there are no studies showing the effect of this compound on the histology and biochemistry of the infected liver. Similarly, it is not evidenced if treatment with GSH can exert a protective effect in the liver of *Plasmodium*-infected subjects. In this context, the current study was aimed at evaluating the effect of GSH and vitamin C treatments on the malaria outcome and in the liver injury of mice infected with *Plasmodium berghei* ANKA (PbA), which represent a well-established animal model of malaria [21, 22].

2. Materials and Methods

2.1. Animals. Male and female BALB/c mice (4–6 weeks old), weighing 20–25 g, were obtained from Animal Care Facilities of the Biological Sciences Institute, Federal University of Para. Animals were housed under specific pathogen-free conditions with fresh water and standard rodent food *ad libitum*. Mice were maintained in groups of 10 animals per cage at controlled room temperature (22-24°C) in a 12-hour light/dark cycle. Experiments were carried out in agreement with Institutional Animal Ethics Committee guidelines (Protocol Number 2229290317), and all efforts were made to minimize animal suffering.

2.2. *Plasmodium berghei* ANKA Infection and Antioxidant Treatment. Blood aliquots containing the *Plasmodium berghei* ANKA (PbA) strain were maintained in liquid nitrogen frozen stock solutions until experimental procedures. Mice were inoculated intraperitoneally (i.p.) with 10^6 parasitized red blood cells (pRBCs), suspended in 200 μl of phosphate-buffered saline (PBS; pH 7.4) as previously described by Ataide et al. [23]. Treatments with GSH (8 mg/kg/day diluted in 100 μl PBS) or vitamin C (8 mg/kg/day diluted in 100 μl PBS) were performed by i.p. injection one hour after infection with PbA. Control mice received the same volume of sterile phosphate-buffered saline solution. The treatment was performed daily, from day 1 to day 7 postinfection. Based on the treatment, mice (*n* = 28) were randomly assigned into four groups: uninfected control, PbA-infected mice, PbA-infected mice+8 mg/kg GSH, and PbA-infected mice+8 mg/kg vitamin C.

2.3. Survival Rate and Blood Parasitemia. Mice from the different groups were monitored every three days for illness clinical sign, body weight, survival rate, and blood parasitemia. Animal body weights were regularly measured during the course of the disease. PbA-infected and antioxidant-treated animals were assessed daily, and the time of death was promptly registered to determine the survival rate curve, as previously described by Oliveira et al. [24]. Parasitemia of individual mice was also measured by staining thin tail blood smears with 10% Giemsa solution (Sigma-Aldrich; diluted in PBS). Parasitemia (percentage of pRBCs) was evaluated by microscopic count and calculated as follows: (number of pRBCs)/(total numbers of RBCs counted) × 100.

2.4. Liver Histopathology. For histopathological analysis, at the 10th day postinfection, PbA-infected and treated mice were first anesthetized with a solution of ketamine (100 mg/kg) and xylazine (10 mg/kg) and euthanatized by cervical dislocation as previously described by Okokon et al. [25]. The liver was aseptically collected by total hepatectomy, and samples were fixed in Bouin’s solution (picric acid, 750 ml; formaldehyde, 250 ml; and acetic acid, 5 ml) for 48 hours. Then, they were progressively dehydrated with increased concentration of alcohol (70%, 80%, 90%, 95%, and 100%) for 40 minutes each. Subsequently, the samples were diaphanized in xylol twice for 30 minutes and paraffinized (58-60°C) for 60 minutes, forming paraffin blocks. Finally, the tissue blocks were cut with the aid of a microtome at a thickness of 5 μm, followed by the assembly of histological slides. Then, deparaffinization was performed for 24 hours in a drying oven at 56°C, followed by hydration of the cuts through a sequence baths in xylol I, xylol II, absolute alcohol I, absolute alcohol II, and alcohol 95%, 80%, and 70% for three minutes each and distilled water for five minutes each. Slides were then stained with hematoxylin for 5 minutes and counterstained with eosin for one minute and, after successive washes, mounted on Permount (Fisher Scientific).

Liver sections were visualized under a light microscope (Nikon, Eclipse E800 Yokohama, Japan) and photographed at 200x magnification. Histological alterations in the tissue were semiquantitatively scored as described previously by Viriyavejakul et al. [26]. Briefly, double-blind analysis was performed in order to determine the presence of steatosis, hyperplastic Kupffer cells, sinusoidal congestion,
and hemozoin deposition. Each parameter was graded on a scale from 0 to 3: 0 = absent, 1 = mild, 2 = moderate, and 3 = severe. The total liver alteration score was expressed as the sum of the scores for each parameter with 12 being the maximum.

2.5. Biochemical Parameters of Liver Injury. The hepatocellular injury was assessed by evaluation of serum biomarkers of liver damage such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total and direct bilirubin (BT and BD). Briefly, at the 10th day postinfection, PbA-infected and treated animals were properly anesthetized and blood samples were collected by cardiac puncture. After centrifugation (3500 rpm for 10 minutes), the supernatant was removed and stored in a low-temperature freezer at \(-80^\circ\text{C}\) until the biochemical test. Serum biochemical assays were conducted in accordance with the commercial kit instructions and determined in a spectrophotometer at a wavelength of 340 nm.

2.6. Statistical Analysis. Kaplan-Meier curves were generated for survival data, and significance was assessed by the Mantel-Cox logrank test \((p \leq 0.05)\); (b) body weight variation between groups during the infection (%). Results are representative of three independent experiments. Results shown are mean \(\pm\) SD.

3. Results

3.1. GSH and Vitamin C Treatments Modify the Survival Curve and Parasitemia Rate of PbA-Infected Mice. To describe the effect of GSH and vitamin C on the clinical progression of PbA-infected mice, animals were treated with 8 mg/kg/day of GSH and vitamin C, separately, for 7 consecutive days. As expected, during PbA infection, BALB/c mice developed characteristic clinical manifestations such as anemia, hepatosplenomegaly, and physical inactivity between the 17th and 29th days postinfection.

Our data showed that during PbA infection, nontreated animals were able to survive until 29 days postinfection; however, the treatment with 8 mg/kg GSH promoted a significant decrease in the survival of PbA-infected mice, with animals dying between days 17 and 19 postinfection (d.p.i). Furthermore, we also observed that 100% of PbA-infected animals treated with GSH died in the 23rd d.p.i. while the PbA-infected group survived until the 29th d.p.i. (Figure 1(a)).

On the other hand, vitamin C treatment promoted an improvement in the disease clinical outcomes and expanded the survival time of the PbA-infected group. Figure 1(a) demonstrates that 50% of animals treated with 8 mg/kg vitamin C died between the 25th and 27th d.p.i. and 100% only at the 34th d.p.i. Further, GSH and vitamin C also had no effect on body weight average in PbA-infected mice and PbA-infected animals treated with antioxidants (Figure 1(b)).

All data are representative of at least three independent experiments.

3BioMed Research International
Our results have also shown that 8 mg/kg GSH promoted a fast and time-dependent increase in parasitemia values in PbA-infected animals (Figure 2). On the other hand, treatment with 8 mg/kg vitamin C has induced significant decrease in parasitemia values when compared with the nontreated PbA-infected group. This differential effect exerted by GSH and vitamin C can be better evidenced by mathematical analysis of parasitemia curve time evolution. As observed in Figure 2, PbA-infected animals which were treated with 8 mg/kg GSH or 8 mg/kg vitamin C present elevated and decreased values of the parasitemia saturation coefficient (1.46 and 1.09, respectively) when compared with the nontreated PbA-infected group (1.28).

3.2. GSH and Vitamin C Treatment, Respectively, Exacerbated and Attenuated Hepatic Histopathology Induced by PbA Infection in Mice. To characterize liver histopathological alterations in PbA-infected animals treated with 8 mg/kg glutathione or 8 mg/kg vitamin C, we performed the hematoxylin-eosin staining (Figure 3). As shown in Figure 3, liver tissue sections from uninfected mice and uninfected mice treated with 8 mg/kg GSH or 8 mg/kg vitamin C had no morphological alterations, showing normal cellular architecture with distinct hepatic cells, sinusoidal spaces, and central veins. In PbA-infected animals, the sinusoidal area presented more enlargements, with deposition of hemosidin malaria pigment inside hyperplasic Kupffer cells and few spots with a discreet steatosis (Figure 3).

However, liver histopathological analysis of PbA-infected mice treated with 8 mg/kg GSH showed a more disarrangement of normal hepatic cells with hyperplasia and polymorphonuclear aggregation with increased numbers of inflammatory cells and vascular congestions (Figure 3). Increased cell infiltration including lymphocytes, mononuclear cells, and neutrophils was observed in the liver of PbA-infected mice treated with 8 mg/kg GSH on day 10 postinfection, leading to severe inflammation and tissue damage as evidenced in double-blind histological evaluation (Table 1). In contrast, animals treated with 8 mg/kg vitamin C presented less disarrangement of normal hepatic cells with few hyperplasia and polymorphonuclear aggregation, decreased numbers of inflammatory cells, and vascular congestions in comparison with nontreated PbA-infected mice. Vitamin C also decreased cell infiltration including lymphocytes, mononuclear cells, and neutrophils decreasing inflammatory response and liver damage in infected animals (Table 1).

3.3. Biochemical Measure of Liver Injuries in PbA-Infected Mice Treated with GSH and Vitamin C. To further assess functional changes, biochemical parameters of liver function were evaluated in the serum of uninfected control mice and PbA-infected mice treated with GSH or vitamin C. As shown in Figure 4, PbA-infected mice exhibited significant increase in serum AST, ALT, BD, and BT levels compared with the uninfected group (Figure 4). Moreover, PbA-infected mice treated with 8 mg/kg GSH showed elevated levels of serum AST, ALT, BD, and BT in comparison with both control and PbA-infected mice. However, our data have also shown that PbA-infected animals treated with vitamin C presented markedly reduced serum levels of AST, ALT, BD, and BT similar to those observed in the PbA-infected with GSH or vitamin C. As demonstrated in both human patients and animals models, liver damage during malaria infection occurs as a result of free heme accumulation that triggers severe oxidative stress and stimulates proinflammatory response by tumor necrosis factor (TNF-α) release [27–29].

During malaria infection, liver dysfunction is often associated with elevated values of blood parasitemia [30–32], and data presented in our study show that mice infected with Plasmodium berghei ANKA demonstrated a time-dependent increase in parasitemia rates as well as intense liver damage as demonstrated by biochemical measurement (AST, ALT, and bilirubin levels). This is in agreement with the literature which describes a positive
The correlation between malaria hepatopathy and the activation of liver macrophages that phagocytize haemozoin or parasitized erythrocytes [12]. Our findings are also supported by previous studies demonstrating that the animal model represents a powerful and valuable tool to evaluate tissue and organ dysfunctions elicited by malaria [33, 34].

Data presented in our study have demonstrated that GSH treatment has favored infection and increased liver toxicity in PbA-infected mice. Although GSH represents an important antioxidant molecule in distinct tissue and organs, there are strong evidences demonstrating that species of the Plasmodium genus use GSH as a substrate for their reproduction in the vertebrate host [35–37]. Our results are in agreement with these reports since GSH treatment has induced a fast increase in parasitemia values; also, it has decreased animal survival in the PbA-infected group. Indeed, histological and biochemical evaluation in PbA-infected animals gives us strong evidences that GSH treatment exacerbates liver damage elicited by Plasmodium infection. Although more studies should be performed, these findings have relevant clinical implications for populations living in endemic malaria areas which largely use precursor of GSH synthesis such as acetylcysteine for the treatment of liver injuries.

While GSH treatment has favored PbA infection and liver impairment, our data also demonstrated that the treatment with vitamin C has a host beneficial effect in mice developing malaria. Anterior studies have already shown that vitamin C exerts a protective action in Plasmodium-infected animals [38–40]. Our study demonstrates that vitamin C treatment attenuates parasitemia evolution and prevents liver damage induced by malaria. Evidence of hepatic damage in the current study included events such as inflammation in the portal tract, hemozoin deposition, sinusoid congestion, and hyperplasia of Kupffer cells, and treatment with vitamin C proved to be effective in preventing these events. Our data are in accordance with previous reports which demonstrate the preventive effect of vitamin C on the hepatocytes in different models of liver injuries [41–43]. It is also well reported that alterations in the redox status of the liver is a mediating phenomenon of Plasmodium infection [44–46]. In this context, we hypothesized...
that vitamin C prevents liver damage in PbA-infected mice by avoiding oxidative stress induced by parasite infection.

Taken together, the data presented in the current study let us hypothesize that during Plasmodium infection, GSH and vitamin C are differently used in the host-parasite relation. In other words, while GSH could favor parasite reproduction and their life cycle, vitamin C acts preferentially in the host as a liver protective molecule.

5. Conclusions

In conclusion, this study demonstrated that, in BALB-C mice, the Plasmodium berghei ANKA strain induces a chronic infection and liver damage which could be differently modulated by the use of antioxidants. The treatment with GSH aggravated the disease outcome and liver injury, and, on the other hand, the treatment with vitamin C protects the liver from damage and the evolution of the disease.

Data Availability

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.
Conflicts of Interest
The authors declare that they have no competing interests.

Authors’ Contributions
Nayara Kaufmann performed and acquired all the experimental data. Luana K. R. L. da Penha performed the infection procedures. Danielle V. Braga performed and analyzed the biochemical data. Brenda J. de A. Ataide performed the histological analyses. Nívia de S. F. Mendes performed the histological analyses. Laiane P. de Sousa performed the infection procedures. Givago da S. Souza performed and analyzed statistical data. Adelaide da C. F. Passos revised the manuscript and statistical analysis. Evander de J. O. Batista contributed to the article final drafting. Anderson M. Herculano analyzed and interpreted the data. Karen R. H. M. Oliveira conceived, designed, and supervised the study.

Acknowledgments
This work was supported by grants from CAPES and CNPq.

References
[1] A. A. Escalante and M. A. Pacheco, "Malaria molecular epidemiology: an evolutionary genetics perspective," Microbiology Spectrum, vol. 7, no. 4, 2019.

[2] R. Varo, C. Chaccour, and Q. Bassat, "Actualizacion en malaria," Medicina Clínica (Barcelona), vol. 155, no. 9, pp. 395–402, 2020.

[3] WHO, World Malaria Report, World Health Organization, 2019.

[4] S. L. Rei Yan, F. Wakasuqui, C. Wrenger, and C. Wrenger, "Point-of-care tests for malaria: speeding up the diagnostics at the bedside and challenges in malaria cases detection," Diagnostic Microbiology and Infectious Disease, vol. 98, no. 3, p. 115122, 2020.

[5] G. D. Shanks, "Historical review: problematic malaria prophylaxis with quinine," The American Journal of Tropical Medicine and Hygiene, vol. 95, no. 2, pp. 269–272, 2016.

[6] J. H. Im, H. Y. Kwon, J. Baek et al., "Severe Plasmodium vivax infection in Korea," Malaria Journal, vol. 16, no. 1, p. 51, 2017.

[7] F. Val, S. Avalos, A. A. Gomes et al., "Are respiratory complications of Plasmodium vivax malaria an underestimated problem?," Malaria Journal, vol. 16, no. 1, p. 495, 2017.

[8] A. Rossati, O. Bargiacchi, V. Kroumovova, M. Zaramella, A. Caputo, and P. L. Garavelli, "Climate, environment and transmission of malaria," Le Infezioni in Medicina, vol. 24, no. 2, pp. 93–104, 2016.

[9] S. Muller, "Role and regulation of glutathione metabolism in Plasmodium falciparum," Molecules, vol. 20, no. 6, pp. 10511–10534, 2015.

[10] U. Frevert, S. Engelmann, S. Zougbede et al., "Intravital observation of Plasmodium berghei sporozoite infection of the liver," PloS Biology, vol. 3, no. 6, p. e192, 2005.

[11] D. Scaccabarozzi, K. Deroost, Y. Corbett et al., "Differential induction of malaria liver pathology in mice infected with Plasmodium chabaudi AS or Plasmodium berghei NK65," Malaria Journal, vol. 17, no. 1, p. 18, 2018.

[12] S. A. Mikolajczak, A. M. Vaughan, N. Kangvanrangsan et al., "Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice," Cell Host & Microbe, vol. 17, no. 4, pp. 526–535, 2015.

[13] R. Raphemot, D. Posfai, and E. R. Derbyshire, "Current therapies and future possibilities for drug development against liver-stage malaria," The Journal of Clinical Investigation, vol. 126, no. 6, pp. 2013–2020, 2016.

[14] K. E. Rankin, S. Graewe, T. H. Heussler, and R. R. Stanway, "Imaging liver-stage malaria parasites," Cellular Microbiology, vol. 12, no. 5, pp. 569–579, 2010.

[15] M. S. Nobes, H. Ghabrial, K. M. Simms, R. B. Smallwood, D. J. Morgan, and R. B. Sewell, "Hepatic Kupffer cell phagocytotic function in rats with erythrocytic-stage malaria," Journal of Gastroenterology and Hepatology, vol. 17, no. 5, pp. 598–605, 2002.

[16] A. B. Rupani and A. D. Amarapurkar, "Hepatic changes in fatal malaria: an emerging problem," Annals of Tropical Medicine and Parasitology, vol. 103, no. 2, pp. 119–127, 2009.

[17] J. Delhaye, O. Glaizot, and P. Christe, "The effect of dietary antioxidant supplementation in a vertebrate host on the infection dynamics and transmission of avian malaria to the vector," Parasitology Research, vol. 117, no. 7, pp. 2043–2052, 2018.

[18] C. L. U. Shelly, "Glutathione synthesis," Biochimica et Biophysica Acta, vol. 1830, no. 5, pp. 3143–3153, 2013.

[19] J. Vega-Rodriguez, R. Pastrana-Mena, K. N. Crespo-Lladó, J. G. Ortiz, I. Ferrer-Rodriguez, and A. E. Serrano, "Implications of glutathione levels in the Plasmodium berghei response to chloroquine and artemisinin," PLoS One, vol. 10, no. 5, article e0128212, 2015.

[20] M. Esmaeili Zadeh, M. Hosseini, F. Beheshti et al., "Vitamin C improves liver and renal functions in hypothyroid rats by reducing tissue oxidative injury," International Journal for Vitamin and Nutrition Research, vol. 90, no. 1-2, pp. 84–94, 2020.

[21] S. Bagot, M. I. Boubou, S. Campino et al., "Susceptibility to experimental cerebral malaria induced by Plasmodium berghei ANKA in inbred mouse strains recently derived from wild stock," Infection and Immunity, vol. 70, no. 4, pp. 2049–2056, 2002.

[22] V. Combes, J. B. De Souza, L. Rénia, N. H. Hunt, and G. E. Grau, "Cerebral malaria: which parasite? Which model?," Drug Discovery Today: Disease Models, vol. 2, no. 2, pp. 141–147, 2005.

[23] B. J. A. Ataide, N. Kauffmann, N. S. F. Mendes et al., "Melatonin prevents brain damage and neurocognitive impairment induced by Plasmodium berghei ANKA infection in murine model of cerebral malaria," Frontiers in Cellular and Infection Microbiology, vol. 10, p. 541624, 2020.

[24] K. R. H. M. Oliveira, N. Kauffmann, L. K. R. Leão et al., "Cerebral malaria induces electrophysiological and neurochemical impairment in mice retinal tissue: possible effect on glutathione and glutamatergic system," Malaria Journal, vol. 16, no. 1, p. 440, 2017.

[25] J. E. Okokon, J. O. Simeon, and E. E. Umoh, "Hepatoprotective activity of the extract of Homalium letestui stem against paracetamol-induced liver injury," Avicenna J Phytomed., vol. 7, no. 1, pp. 27–36, 2017.

[26] P. Viriyavejakul, V. Khachonsaksuth, and C. Punsawad, "Liver changes in severe Plasmodium falciparum malaria:
histopathology, apoptosis and nuclear factor kappa B expression,” *Malaria Journal*, vol. 13, no. 1, 2014.

[27] S. Dey, S. Bindu, M. Goyal et al., “Impact of intravascular hemolysis in malaria on liver dysfunction: involvement of hepatic free heme overload, NF-κB activation, and neutrophil infiltration,” *The Journal of Biological Chemistry*, vol. 287, no. 32, pp. 26630–26646, 2012.

[28] S. Percário, D. R. Moreira, B. A. Q. Gomes et al., “Oxidative stress in malaria,” *International Journal of Molecular Sciences*, vol. 13, no. 12, pp. 16346–16372, 2012.

[29] T. N. Nguyen, S. Baaklini, F. Koukouikila-Koussounda et al., “Association of a functional TNF variant with Plasmodium falciparum parasitaemia in a Congolese population,” *Genes and Immunity*, vol. 18, no. 3, pp. 152–157, 2017.

[30] A. M. Vaughan and S. H. I. Kappe, “Malaria parasite liver infection and exoerythrocytic biology,” *Cold Spring Harbor Perspectives in Medicine*, vol. 7, no. 6, article a025486, 2017.

[31] P. D. S. Ventura, C. P. F. Carvalho, N. M. T. Barros et al., “Malaria infection promotes a selective expression of kinin receptors in murine liver,” *Malaria Journal*, vol. 18, no. 1, p. 213, 2019.

[32] A. Odedra, L. Webb, L. Marquart et al., “Liver function test abnormalities in experimental and clinical Plasmodium vivax infection,” *The American Journal of Tropical Medicine and Hygiene*, vol. 103, no. 5, pp. 1910–1917, 2020.

[33] H. C. Van Der Heyde, P. Bauer, G. Sun et al., “Assessing vascular permeability during experimental cerebral malaria by a radiolabeled monoclonal antibody technique,” *Infection Immun.*, vol. 69, no. 5, pp. 3460–3465, 2001.

[34] T. Taniguchi, E. Miyachi, S. Nakamura et al., “Plasmodium berghei ANKA causes intestinal malaria associated with dysbiosis,” *Nature*, vol. 5, p. 15699, 2015.

[35] V. Padin-Irizarry, E. E. Colón-Lorenzo, J. Vega-Rodriguez et al., “Glutathione-deficient _Plasmodium berghei_ parasites exhibit growth delay and nuclear DNA damage,” *Free Radical Biology and Medicine*, vol. 95, pp. 43–54, 2016.

[36] E. Jortzik and K. Becker, “Thioredoxin and glutathione systems in _Plasmodium falciparum_,” *International Journal of Medical Microbiology*, vol. 302, no. 4–5, pp. 187–194, 2012.

[37] G. Kapoor and H. S. Banyal, “Glutathione reductase and thioredoxin reductase: novel antioxidant enzymes from Plasmodium berghei,” *The Korean Journal Parasitology*, vol. 47, no. 4, pp. 421–424, 2009.

[38] X. Qin, J. Liu, Y. Du et al., “Different doses of vitamin C supplementation enhances the Th1 immune response to early Plasmodium yoelii 17 XL infection in BALB/c mice,” *International Immunopharmacology*, vol. 70, pp. 387–395, 2019.

[39] M. Z. Rahifiludin and P. Ginandjar, “The effect of zinc and vitamin C supplementation on hemoglobin and hematocrit levels and immune response in patients with Plasmodium vivax malaria,” *The Southeast Asian Journal of Tropical Medicine and Public Health*, vol. 44, no. 5, pp. 733–739, 2013.

[40] I. Mgbemena and C. Ifeyinwa, “The efficacy of antioxidant (vitamin C) in the treatment and management of malaria,” *Advances in Biotechnology & Microbiology*, vol. 15, no. 4, p. 555919, 2020.

[41] M. Su, X. Liang, X. Xu, X. Wu, and B. Yang, “Hepatoprotective benefits of vitamin C against perfluorooctane sulfate-induced liver damage in mice through suppressing inflammatory reaction and ER stress,” *Environmental Toxicology and Pharmacology*, vol. 65, pp. 60–65, 2019.

[42] M. Su, H. Chen, C. Wei, N. Chen, and W. Wu, “Potential protection of vitamin C against liver-lesioned mice,” *International Immunopharmacology*, vol. 22, no. 2, pp. 492–497, 2014.

[43] Y. Okamura, A. Omori, N. Asada, and A. Ono, “Effects of vitamin C and E on toxic action of alcohol on partial hepatectomy-induced liver regeneration in rats,” *Journal of Clinical Biochemistry and Nutrition*, vol. 63, no. 1, pp. 50–57, 2018.

[44] K. Deroost, N. Lays, T. Pham et al., “Hemozoin induces hepatic inflammation in mice and is differentially associated with liver pathology depending on the Plasmodium strain,” *PLoS One*, vol. 9, no. 11, 2014.

[45] M. A. Dkhil, E. M. Al-Shaebi, and S. Al-Quraishy, “Effect of Indigofera oblongifolia on the hepatic oxidative status and expression of inflammatory and apoptotic genes during blood-stage murine malaria,” *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 8264861, 7 pages, 2019.

[46] A. Sengupta, A. Basant, S. Ghosh, S. Sharma, and H. M. Sonawat, “Liver metabolic alterations and changes in host intercompartmental metabolic correlation during progression of malaria,” *Journal of Parasitology Research*, vol. 2011, Article ID 901854, 14 pages, 2011.